Docetaxel

About

Therapy type: Chemotherapy

Therapy strategy: Taxane-based chemotherapy

Mappings

NCI Thesaurus: Docetaxel (ncit:C1526)

View API

Therapeutic response

Precision oncology relationships for therapeutic response involving this therapy.

Organization(s) Biomarker(s) Cancer type Therapy(ies)
EMA (4) FDA (2) HER2-positive Invasive Breast Carcinoma Docetaxel, Pertuzumab, Trastuzumab
EMA (1) FDA (4) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Docetaxel, Epirubicin, Fluorouracil, Pertuzumab, Trastuzumab
EMA (2) FDA (2) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Docetaxel, Doxorubicin, Fluorouracil, Pertuzumab, Trastuzumab
EMA (2) FDA (2) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Docetaxel, Epirubicin, Pertuzumab, Trastuzumab
FDA (2) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Docetaxel, Doxorubicin, Pertuzumab, Trastuzumab
EMA (2) FDA (2) HER2-positive Invasive Breast Carcinoma Carboplatin, Docetaxel, Pertuzumab, Trastuzumab
EMA (3) HER2-positive Invasive Breast Carcinoma Docetaxel, Trastuzumab
EMA (3) ERBB2 amplification Invasive Breast Carcinoma Docetaxel, Trastuzumab
EMA (1) HER2-positive Invasive Breast Carcinoma Carboplatin, Docetaxel, Trastuzumab
EMA (1) ERBB2 amplification Invasive Breast Carcinoma Carboplatin, Docetaxel, Trastuzumab
EMA (1) PD-L1 >= 1% Non-Small Cell Lung Cancer Cisplatin, Docetaxel, Nivolumab